Humacyte (NASDAQ:HUMA – Get Free Report) had its target price upped by analysts at Benchmark from $15.00 to $17.00 in a research report issued on Monday,Benzinga reports.The brokerage currently ...
In other Humacyte news, Director Brady W. Dougan sold 427,459 shares of the business’s stock in a transaction on Tuesday, November 19th. The stock was sold at an average price of $4.34, for a ...
https://www.tipranks.com/news/the-fly/vertex-pharmaceuticals-price-target-lowered-to-460-from-550-at-truist Benchmark analyst Bruce Jackson raised the firm’s price ...
NEW YORK, Dec. 24, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Humacyte, Inc. (NASDAQ: HUMA) between May 10, 2024 and October 17 ...
STORY HIGHLIGHTS FDA approved Humacyte's Symvess for vascular trauma treatment. Symvess is a bioengineered human tissue vascular conduit. Humacyte plans commercial launch and technology expansion.
Financial giants have made a conspicuous bearish move on Humacyte. Our analysis of options history for Humacyte (NASDAQ:HUMA) revealed 9 unusual trades. Delving into the details, we found 11% of ...
DURHAM, N.C., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a biotechnology platform company developing universally implantable, bioengineered ...
On Thursday, H.C. Wainwright adjusted its financial outlook for shares of Humacyte (NASDAQ: HUMA), increasing the price target to $15.00 from the previous $12.00 while reaffirming a Buy rating.
Humacyte (NASDAQ:HUMA) shares climbed ~57% in the premarket on Friday after the bioengineered tissue maker announced the FDA approval of Symvess, an off-the-shelf, implantable vascular conduit ...